Wyeth makes deal to boost biotech business

Wyeth has reached an agreement with Trubion Pharmaceuticals to develop and market antibody-like drugs as part of an effort to boost its biotechnology business. The deal, worth up to $800 million, gives Wyeth access to potential cancer and immune-system disorder drugs.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA